{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-014932","form_type":"8-K","ticker":"HRMY","cik":"0001802665","company_name":"Harmony Biosciences Holdings, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.305532+00:00","generated_at":"2026-06-11T12:17:31.878465+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Harmony Biosciences to acquire Zynerba for $1.1059 cash + CVR up to $2.5444 per share","bullets":["Total potential consideration up to ~$3.65/share: $1.1059 cash plus a CVR worth up to $2.5444 upon milestones.","CVR milestones include Zygel pivotal study completion, NDA approvals, and sales thresholds aggregating up to $140M.","Zynerba directors/officers holding ~6.9% of shares have agreed to tender their shares in support.","Tender offer minimum condition: at least one share more than 50% of outstanding Zynerba shares must be tendered.","Termination fee of $4.5M payable by Zynerba if it accepts a superior proposal in certain circumstances."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-014932","json":"https://secwatch.observer/filing/0001558370-23-014932.json","markdown":"https://secwatch.observer/filing/0001558370-23-014932.md","text":"https://secwatch.observer/filing/0001558370-23-014932.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023014932/0001558370-23-014932-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023014932/hrmy-20230814x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T12:17:31.878465+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b3d5d8dd3a97b8a7ab12467ee4b229166b95344e","claim":"Harmony Biosciences Holdings, Inc. entered into Agreement and Plan of Merger with Zynerba Pharmaceuticals, Inc. (effective 2023-08-14).","evidence_excerpt":"On August 14, 2023, Harmony Biosciences Holdings, Inc., a Delaware corporation (the “Company”) and Xylophone Acquisition Corp., a Delaware corporation and a wholly owned, direct subsidiary of the Company (“Merger Sub”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Zynerba Pharmaceuticals, Inc., a Delaware corporation (“Zynerba”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023014932/0001558370-23-014932-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Zynerba Pharmaceuticals, Inc."},{"label":"Effective","value":"2023-08-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}